View Older Stories View More Recent Stories

May 12, 2022 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 3, 2022 08:05AM Alpine Immune Sciences Announces Participation in May Investor Conferences
Apr 12, 2022 05:05PM AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
Apr 5, 2022 04:05PM Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event
Apr 4, 2022 08:06AM Alpine Immune Sciences (ALPN) Reports Key Preclinical Rationale for Davoceticept (ALPN-202)
Apr 4, 2022 08:05AM Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
Mar 30, 2022 08:05AM Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
Mar 17, 2022 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Mar 8, 2022 04:35PM Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting
Mar 7, 2022 08:06AM Alpine Immune Sciences (ALPN) Announces FDA Placed Partial Clinical Hold on NEON-2 Trial of Davoceticept in Combination with Pembrolizumab
Mar 7, 2022 08:05AM Alpine Immune Sciences Reports FDA Partial Clinical Hold on NEON-2 Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
Mar 1, 2022 08:05AM Alpine Immune Sciences Announces Participation in March Investor Conferences
Jan 4, 2022 04:05PM Alpine Immune Sciences Announces Participation in January Investor Conferences
Dec 16, 2021 08:02AM Alpine Immune Sciences (ALPN) and Horizon Therapeutics (HZNP) Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Dec 16, 2021 08:00AM Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Dec 16, 2021 08:00AM Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Nov 22, 2021 04:05PM Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference
Nov 10, 2021 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Nov 8, 2021 08:05AM Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting
Sep 15, 2021 08:05AM Alpine Immune Sciences (ALPN) Announces $91M Private Placement of Stock and Warrants
Sep 15, 2021 08:05AM Alpine Immune Sciences Announces $91 Million Private Placement
Sep 7, 2021 04:05PM Alpine Immune Sciences Announces Participation in September Investor Conferences
Aug 10, 2021 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Aug 4, 2021 08:00AM Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences
Jun 30, 2021 08:04AM Alpine Immune Sciences (ALPN) to Collaborate with Merck (MRK) on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA
Jun 30, 2021 08:00AM Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)
Jun 24, 2021 08:02AM Alpine Immune Sciences (ALPN) Doses First Patient in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial, $45M Milestone Achieved
Jun 24, 2021 08:00AM Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration
Jun 8, 2021 08:00AM Alpine Immune Sciences Set to Join Russell 3000® Index
Jun 4, 2021 04:05PM Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting
Jun 2, 2021 04:05PM Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting
Jun 2, 2021 08:04AM Alpine Immune Sciences (ALPN) Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer
Jun 2, 2021 08:00AM Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer
May 19, 2021 05:10PM Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting
May 18, 2021 04:05PM Alpine Immune Sciences Announces Oral Presentation at the 2021 EULAR Virtual Meeting
May 13, 2021 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results
Apr 28, 2021 04:05PM Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting
Apr 12, 2021 08:11AM Alpine Immune Sciences (ALPN) Presents Clinical and Preclinical Oncology Program Updates at AACR Virtual Annual Meeting I
Apr 12, 2021 08:00AM Alpine Immune Sciences Presents Clinical and Preclinical Oncology Program Updates at AACR Virtual Annual Meeting I
Mar 18, 2021 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 11, 2021 04:05PM Alpine Immune Sciences to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Mar 10, 2021 04:30PM Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I
Feb 22, 2021 04:05PM Alpine Immune Sciences to Participate in Upcoming Virtual Healthcare Conferences
Jan 6, 2021 08:00AM Alpine Immune Sciences Announces Executive Leadership Addition and Promotion
Dec 17, 2020 08:00AM Alpine Immune Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference
Dec 11, 2020 08:00AM Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
Nov 24, 2020 04:05PM Alpine Immune Sciences to Participate in Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
Nov 16, 2020 04:05PM Alpine Immune Sciences to Participate in Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 12, 2020 04:05PM Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Nov 5, 2020 04:05PM Alpine Immune Sciences to Report Third Quarter 2020 Financial Results and Provide Corporate Update
View More Recent Stories View Older Stories